North America is expected to remain a significant region in the alpha emitters market through 2034, supported by the growing adoption of targeted alpha therapies, increasing investment in radiopharmaceutical research, and advancements in nuclear medicine. The region benefits from a well-established healthcare infrastructure, strong pharmaceutical and biotechnology capabilities, and substantial...